Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer [Yahoo! Finance]
Leap Therapeutics, Inc. (LPTX)
Last leap therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.leaptx.com
Company Research
Source: Yahoo! Finance
combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm). The trial enrolled patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease The updated analysis shared on Wednesday includes the overall response rate (ORR), an additional two months of patient follow-up for progression-free survival (PFS), and initial overall survival (OS) data. Also Read: Visionary Holdings Launches New Fund In Hong Kong To Propel New Energy Vehicle Industry: Details As of March 12, 2025, 34 patients remain on the study drug in the sirexatamab Experimental Arm compared to 24 patients in the Control Arm. In patients with high DKK1 levels, the sirexatamab Experimental Arm has a statistically significant 32% higher ORR, 3.5 months longer PFS, and OS compared to the Control Arm: In patients who had not received prior anti-VEGF therapy, the sirexatamab Expe
Show less
Read more
Impact Snapshot
Event Time:
LPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPTX alerts
High impacting Leap Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LPTX
News
- Leap Therapeutics (NASDAQ:LPTX) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e+)" rating on the stock.MarketBeat
- Solana in the Shade: Crypto Daybook Americas [Yahoo! Finance]Yahoo! Finance
- Will Winklevoss Twins Successfully Takeover ZCash? [Yahoo! Finance]Yahoo! Finance
- Winklevoss-backed stock halted multiple times after wild 550% rally [Yahoo! Finance]Yahoo! Finance
- BC-Most Active Stocks [Yahoo! Finance]Yahoo! Finance
LPTX
Earnings
- 11/12/25 - Beat
LPTX
Sec Filings
- 11/12/25 - Form DEFA14A
- 11/12/25 - Form 8-K
- 11/12/25 - Form 424B5
- LPTX's page on the SEC website